Shares of Vir Biotechnology Inc. (VIR) gained 1.9% in premarket trading on Wednesday after the company and GlaxoSmithKline (GSK.LN) said the European Commission purchased 220,00 doses of their investigational COVID-19 antibody treatment. The therapy is a single-dose monoclonal antibody that is being tested as a treatment to ward off severe disease in some high-risk COVID-19 patients. The European Medicines Agency is currently reviewing the companies' application for sotrovimab. (Sotrovimab received emergency authorization (http://www.marketwatch.com/story/the-fda-authorized-the-third-monoclonal-antibody-treatment-heres-why-vir-and-gsk-say-the-u-s-still-needs-covid-19-therapies-11622133248) in the U.S. in May, and it has also been authorized in Qatar, Singapore, and the United Arab Emirates.) Vir's stock is up 36.0% for the year, while the S&P 500 has gained 17.2%.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.